Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CAT delays plans to reach profitability
In a financial update for the first six months of its fiscal year, the UK biotech firm stated that its previous articulated goal of achieving profitability by 2008
In a financial update for the first six months of its fiscal year, the UK biotech firm stated that its previous articulated goal of achieving profitability by 2008
The team’s analysis of four microRNAs (miRNA) found in the blood plasma of pancreatic cancer patients is proof of principle to further develop a blood test for this
In the study, eight of 33 patients with advanced, refractory cutaneous T-cell lymphoma (CTCL) experienced partial responses, the primary endpoint of the study. The most common side effects
A review compared the treatment responses of 1,177 patients from ten clinical trials in which Bexxar was used as either first-line, second-line, third-line, or fourth-line (or greater) treatment.
Results from an interim analysis of this study showed that the median progression-free survival was 11 months for patients treated with Avastin (bevacizumab) plus chemotherapy, compared to six
Pegasys (peginterferon alfa-2a) is now approved for both variations of the chronic hepatitis B virus – HBeAg-positive and HBeAg-negative. Pegasys was approved in 2002 by the FDA for
Study data showed that, after four years, 15% of women treated with Herceptin plus chemotherapy experienced disease recurrence, compared to 33% of women treated with chemotherapy alone. Preliminary
Femara (letrozole tablets) prolonged disease free survival by reducing the risk of recurrence an additional 19% over that offered by tamoxifen when used as initial treatment after surgery,
The phase III study, conducted by the Eastern Cooperative Oncology Group (ECOG), involved 878 patients who were randomized to standard chemotherapy – paclitaxel and carboplatin – with and
At the same time, the company has secured a $2 million investment from a private investor to support the MDR-TB (multiple drug-resistant tuberculosis) drug development and clinical trial